Recent News
Read ArticleWhen it rains it pours, but when it comes to grief, it’s like the rains that just won't let up.
Just too many deaths this past month. All devastating, all my immediate sphere. All hard to fathom. How can something so inevitable be a recurring, unwelcome, unsolvable bad dream?
Beyond Disease Modification: Palliative Care in Rheumatology
Therapeutic advances have transformed the prognosis of many rheumatic diseases, allowing patients to achieve sustained disease control and avoid irreversible organ damage. For some, however, rheumatology conditions progressively cause decline, damage, loss of function, and ultimately shortened life expectancy. Palliative care is an under-utilized and often misunderstood tool within rheumatology.
Read Article
Southern Israel study (2009-24) shows fibromyalgia prevalence Incr from 1.04% to 3.88%, esp 30-59 yrs; more males, w/ more Psych comorbidities; fewer hospitalizations & specialist visits but increased imaging. More use of pregabalin, duloxetine, & gabapentin. https://t.co/kgmvdZF9HQ
Dr. John Cush @RheumNow ( View Tweet)
Systematic review of 290 psoriasis pregnancies 211 live births (73%) finds biologic exposure (UST 241, 42 TNFi) during PREG assoc w/ favorable maternal/fetal outcomes. Only 24 cont either CZP or ADA throughout PREG. Rates of miscarriage, LBW, congenital anomalies, comparable w/ https://t.co/H5GLrvxwPv
Dr. John Cush @RheumNow ( View Tweet)
Indian Single center retrospective study of 28 children ≤18 yrs tested w/ 18F-FDG-PET/MR for pyrexia (PUO). 25% Dx w/ pre-stenotic TAKayasu (mean 13.9 yrs), & 20/21 alternative Dxs. All had Sxs & high ESR/CRP; all Rx w/ GC & MMF, 3 w/ biologics https://t.co/6trs1WssjW https://t.co/EOPIarRhY5
Dr. John Cush @RheumNow ( View Tweet)
It’s almost time. 🔥
Registration for RheumNow Live 2027 opens OCTOBER 1.
Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice.
📅 Jan 30–31, 2027
📍 Dallas + Online https://t.co/Ju0zzYX8Tl
Dr. John Cush @RheumNow ( View Tweet)
Prescribing New GLP-1-Based Therapies
https://t.co/cpxyxBMZ8s https://t.co/9JXmlW2Lj6
Dr. John Cush @RheumNow ( View Tweet)
New report shows Median total cash compensation increased across all seven specialty groups in 2026; adult medical rose 7.2% - Rheumatology led one-year pay growth at 10.4% https://t.co/iuonfJRsf6 https://t.co/zybCZeNV5I
Dr. John Cush @RheumNow ( View Tweet)
Gabapentin Use Rose as Restrictions Fell, Study Shows
MedPage Today
Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed.
Read Article
Obesity and Psoriatic Disease
Mason Arbabi, MD and Juliana S. Simonetti, MD
Obesity is a clinically important comorbidity in psoriasis and psoriatic arthritis. Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic therapies. Intentional weight loss should be considered an adjunct to appropriate dermatologic and rheumatologic treatment.
Read Article
Early RA Referral Clinics Work (9.18.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/ofGKCCNQnE
https://t.co/fn0L4goAMT https://t.co/F8QKs7261x
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic: GLP-1s and History of Thyroid Cancer?
Daric Mueller, PA-C, St. Clair Shores, MI, presents this case as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026.
https://t.co/rhsUNVIdQ4 https://t.co/mjHEWNIGqU
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic: Bariatric Surgery "Curing" Arthritis?
Dr. Richard Conway, Dublin, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026.
https://t.co/YwtSkroMta https://t.co/tl8eSrvGhq
Dr. John Cush @RheumNow ( View Tweet)
Obesity in Rheumatic Diseases: More than just a Comorbidity
https://t.co/0QJ188HYSm https://t.co/3L09m2cowl
Dr. John Cush @RheumNow ( View Tweet)
Metabolomic/proteomics w/ cardiac MRI & longitudinal outcomes in 488079 UK Biobank pts shows chronic systemic inflammation assoc w/ reduced LV volumes, incr CV risk (cytokines, GFs, IL-1, TNF as potential mediators) https://t.co/3woGOttKHz https://t.co/eJLkPyJe6U
Dr. John Cush @RheumNow ( View Tweet)
Scleroderma-Specific Autoantibodies in Early Systemic Sclerosis
Prognostication is tenous in early scleroderma, especially in those with diffuse cutaneous systemic sclerosis (dcSSc). dcSSc has associated with substantial morbidity and disease-specific mortality. Analysis of an early SSc registry shows that anti-RNA polymerase III autoantibodies in early SSc were associated a higher risk of worse phenotypes and clinical outcomes.
Obesity and Gout: An Old Relationship with New Thoughts
https://t.co/T71u9Ta4NS https://t.co/B7vUVqIBQE
Dr. John Cush @RheumNow ( View Tweet)
🚨 Registration opens October 1!
RheumNow Live 2027 returns January 30–31 for our 9th Annual CME Meeting.
📍 Dallas + Online
📅 January 30–31, 2027
🎓 High-impact CME. Expert faculty. Real-world rheumatology.
The rheumatology meeting that sets the tone for the year ahead. https://t.co/PFZ37DlTQe
Dr. John Cush @RheumNow ( View Tweet)
Systematic review 14 studies assessed Lung ultrasound (LUS) (vs HRCT) to detect RA-ILD (using threshold of ≥ 5 B-lines) found sensitivity was 86.8% (95% CI 80.1–91.4), specificity 75.4% (95% CI 62.3–85.1), and AUC 0.890 https://t.co/GlNpsPBwtS https://t.co/FJ6B5E5CWy
Dr. John Cush @RheumNow ( View Tweet)
FORWARD is a Phase 4, OL trial in 51 refractory uncontrolled gout pts Rx w/ MTX plus higher doses pegloticase (16 or 30mg) IV q4wk. At 24-wk Responses similar 68% or 73%. ~31% of responders later had SUA >6. Confusing anti-Drug Ab results in this trial?? https://t.co/udjE7sXDm5 https://t.co/F8VGDAyJzb
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Obesity QD Clinics Part Three
Obesity Treatment & Safety
The Four PIllars of Weight Loss Part 2-
The Four Pillars of Weight Loss Part 1
Therapeutic Updates
The Four Pillars of Weight Loss
RheumNow
Watch our 'Four Pillars of Weight Loss' 6-part series as part of this month's The Obesity Imperative campaign.
Read Post
Label update: Structural damage progression in active PsA
Sponsored by Johnson & Johnson Medical Affairs
Listen to Dr. Catherine Bakewell’s review of clinical data from a recent label update.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Real-World Joint Outcomes With an IL-23i vs TNFi or IL-17i in PsA
Daily Gem
Obesity undermines RA. High BMI inflates pain and functional scores, while also dampening therapeutic response.
--